Cytomegalovirus pneumonia complicating immune checkpoint inhibitors-induced pneumonitis: A case report

A 63-year-old man was hospitalized for immune check-point inhibitors (ICIs) medicated pneumonitis, secondary to treatment with pembrolizumab for non-small cell lung cancer. He was treated with high dose steroids, mycophenolate mofetil, empiric broad spectrum antibiotics and empiric trimethoprim-sulf...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and clinical oncology 2021-06, Vol.14 (6), p.120-120, Article 120
Main Authors: Badran, Omar, Ouryvaev, Anton, Baturov, Veronika, Shai, Ayelet
Format: Article
Language:English
Subjects:
Antibacterial agents
Antiviral agents
Bacterial pneumonia
Cancer
Care and treatment
Case reports
Chronic obstructive pulmonary disease
Complications and side effects
Cytomegalovirus
Cytomegalovirus infections
Disease
Immunosuppressive agents
Immunotherapy
Infections
Lung cancer
Lung cancer, Non-small cell
Metastasis
Mortality
Mycophenolate mofetil
Oncology
Patients
Pneumonia
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A 63-year-old man was hospitalized for immune check-point inhibitors (ICIs) medicated pneumonitis, secondary to treatment with pembrolizumab for non-small cell lung cancer. He was treated with high dose steroids, mycophenolate mofetil, empiric broad spectrum antibiotics and empiric trimethoprim-sulfamethoxazole and intravenous immunoglobulin. Despite the aforementioned treatment, his condition continued to deteriorate. The patient was admitted to the intensive care unit. While intubated, he underwent bronchoscopy and lavage, which was analyzed for potential infectious agents. Cytomegalovirus (CMV) pneumonia was diagnosed and treated. He passed away despite antiviral treatment and maximal supportive care. CMV infection should be suspected in patients failing to recover from toxicities of ICIs with appropriate immunosuppression.
ISSN:2049-9450
2049-9469
DOI:10.3892/mco.2021.2282